Title of article
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial
Author/Authors
John A Baron، نويسنده , , Robert S Sandler، نويسنده , , Robert S Bresalier، نويسنده , , Angel Lanas، نويسنده , , Dion G Morton، نويسنده , , Robert Riddell، نويسنده , , Erik R Iverson، نويسنده , , David L. DeMets، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
9
From page
1756
To page
1764
Abstract
Summary
Background
Selective inhibition of cyclo-oxygenase-2 has been associated with an increased risk of cardiovascular events in several clinical trials. The Adenomatous Polyp Prevention on Vioxx (APPROVe) study assessed the effect of 3-year treatment
Journal title
The Lancet
Serial Year
2008
Journal title
The Lancet
Record number
593726
Link To Document